Microcap pharma stock. Releasing the drug Mugard which helps people handle Chemotherapy - should get about 20% of revenues from this new drug - estimated imcome for company is 70 million a year maximun. They will be selling this Mugard internationally. They have several other very promising drugs coming in type 2 trails - improved existing drugs so they are easier to be accepted then brand new drugs.

Market Cap of this Cancer Pharma is only 17.5 million. IMO this pharma stock will soon be making new highs. Stock has not started to move yet but soon will take off as Mugard sales come in from current US and Europe launch.

Access Pharma has been up 20% then 15% the last 2 days. Today it closed above its resistence level. IMO this stock could double in the next few weeks because of the start of Mugard. The company only burns about 2 million a quarter so they could become profitable very quickly with Mugard revenues. Also ACCP has a great pipeline of new cancer drugs coming. This is a great opportunity.

ACCP seems to have leveled off after a going from $1.50 to $2.25. The capitalization of the stock is about $45 million if you include the several million preferred shares. Access Pharm has launched MuGard globally with several different partners - its a unique polymer drug that coats the mouth with a protective layer thats needed if someone is undergoing radiation or chemotherapy. About 40% of cancer cases could use MuGard to prevent oral bleeding. ACCP will get 20% of all revenues from MuGard which could come to an estimated $80 million a year. This would make ACCP profitable as they are only burning about $2 million a quarter - soon it will be a profitable company.

Also ACCP has several other cancer drugs that are improved versions of current drugs. Its easier to approve a similar drug then to try to establish a totally new drug - many tests have already been done. They are looking for partners who will give them 20% royalties for these new drugs. Prolindac looks very promising in a number of studies and there are several other drugs. The potential market for Prolindac looks to be about $2.5 billion.

What price is a fair valuation of all these promising drugs? I have researched alot of pharmacy companies and this one is way undervalued. IMO ACCP will make new highs soon.

The news from ACCP continues to be great. This company has several drugs in development. MuGard revenues should start this fall.

Disclosure; I own some ACCP in my portfolio.

Listen to the interview with their CEO. The company has an incredible pipeline and MuGard is going on sale globally in the next few months. ACCP is projecting that the company will turn profitable next year with sales from MuGard. They need to find a USA partner for their cancer drug Prolindac - they already have a partner in China and Asia. They also have another cancer drug in their pipeline that should be good against blood cancers. Finally ACCP is developing an oral form of drug delivery that uses vitamen B absorbtion to help against diabities and other complex drugs - 2 companies just signed on as partners.

DALLAS , Sept. 11 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) has entered into an agreement with a leading commercial manufacturer to produce its FDA -approved MuGard for North American distribution. One or more U.S. market seeding studies could begin as early as Q4 2009, the company says.

In a comparison of cancer patients receiving standard oral mucositis care with those patients receiving MuGard , MuGard has been shown to significantly reduce the incidence and severity of the debilitating side effect of radiation treatment and chemotherapy.

Access has contracted with Accupac, Inc. to serve as its commercial manufacturer of MuGard in North America . Accupac manufactures, fills and packages a wide range of consumer commodity, over-the-counter (OTC) and prescription (Rx) products for the world's largest pharmaceutical and consumer products companies.

CLICK HERE FOR FULL ARTICLE


Detailed Quote: OTCPicks.com Microcap and Pennystock Picks, Featured Company Profiles, Stock Blogs, Stock News Alerts, Daily Market Movers Digest Newsletter, Stocks to Watch Newsletter covering OTC, OTCBB and Pinksheets stocks

Company Profile: Access Pharmaceuticals - Featured Small Cap Profile

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac™, currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard™ for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin™-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix®, a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers.

I have continued to add to my long position in ACCP. The stock is sitting at $3.50 a share. I initially started buying at $1.55 a share. Nothing has changed except Access Pharma has been getting impressive results in all their studies in Europe and will soon start some US studies of MuGard. Their European partner will soon start selling in France. ACCP should become profitable sometime next year from European MuGard sales. Asia and US are the next to start MuGard sales. Access should soon have a major US partner - it has a US producer and an advertising partner. ACCP also has a pipeline of several more promising drugs. With a biotech company you find one with great drugs or a unique medical device then you stick with it until it reaches maturity. ACCP is starting to mature but there is still plenty of time to load the boat - the company's market capitalization is still under a $100 million and IMO will go to a billion or more with global MuGard sales and other promising drugs.

disclosure: I have a large position in ACCP